
TY  - JOUR
TI  - Poster Session 3
JO  - European Journal of Heart Failure Supplements
JA  - European Journal of Heart Failure Supplements
VL  - 10
IS  - S1
SN  - 1567-4215
UR  - https://doi.org/10.1093/eurjhf/hsr007
DO  - doi:10.1093/eurjhf/hsr007
SP  - S116
EP  - S161
PY  - 2011
ER  - 

AU  - Harry, G. Jean
AU  - Lein, Pamela J.
C7  - pp. 193-227
TI  - Developmental Neurotoxicity of Dioxins
SN  - 9780470605295
UR  - https://doi.org/10.1002/9781118184141.ch7
DO  - doi:10.1002/9781118184141.ch7
SP  - 193-227
KW  - dioxins, developmental neurotoxicity, altering normalcy
KW  - developmental effects due to dioxin-mediated AhR crosstalk
KW  - TCDD, neurotoxicity, altered, neurogenesis
PY  - 2011
AB  - Summary This chapter contains sections titled: Introduction Epidemiological Studies on Neurodevelopmental Effects of Dioxin Mechanisms of Dioxin Toxicity Overview of Neurodevelopment in the Central Nervous System Potential for Developmental Effects Due to Dioxin-Mediated AHR Activation Experimental Studies on Molecular and Cellular Effects of TCDD in Neural Model Systems Experimental Studies of Neurobehavioral Effects of Developmental Exposure to TCDD Summary References
ER  - 

TY  - JOUR
TI  - Lunchtime Posters
JO  - Colorectal Disease
JA  - Colorectal Dis
VL  - 18
IS  - S1
SN  - 9780470605295
UR  - https://doi.org/10.1111/codi.13444
DO  - doi:10.1111/codi.13444
SP  - 27
EP  - 43
PY  - 2016
ER  - 

TY  - JOUR
TI  - ADF Abstracts 2014
JO  - Experimental Dermatology
JA  - Exp Dermatol
VL  - 23
IS  - 3
SN  - 9780470605295
UR  - https://doi.org/10.1111/exd.12314
DO  - doi:10.1111/exd.12314
SP  - e1
EP  - e60
PY  - 2014
ER  - 

C7  - pp. 584-658
TI  - Cardiac Regenerative Engineering
SN  - 9780471709077
UR  - https://doi.org/10.1002/9780470116869.ch14
DO  - doi:10.1002/9780470116869.ch14
SP  - 584-658
KW  - cardiac regenerative engineering and cardiac disorders
KW  - Vascular endothelial growth factor (VEGF) A
KW  - antioxidant molecules and therapeutic agents
PY  - 2014
AB  - Summary This chapter contains sections titled: Anatomy and Physiology of the Heart Cardiac Disorders
ER  - 

TY  - JOUR
TI  - 41st Annual conference of International Society of Paediatric Oncology SIOP 2009, Sao Paulo, Brazil, October 5–9, 2009
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 53
IS  - 5
SN  - 9780471709077
UR  - https://doi.org/10.1002/pbc.22234
DO  - doi:10.1002/pbc.22234
SP  - 701
EP  - 915
PY  - 2009
ER  - 

TY  - JOUR
TI  - Poster Sessions: Translational
JO  - American Journal of Transplantation
VL  - 14
IS  - S3
SN  - 9780471709077
UR  - https://doi.org/10.1111/ajt.12896
DO  - doi:10.1111/ajt.12896
SP  - 871
EP  - 905
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Fundamental & Clinical Pharmacology
VL  - 24
IS  - s1
SN  - 9780471709077
UR  - https://doi.org/10.1111/j.1472-8206.2010.00819.x
DO  - doi:10.1111/j.1472-8206.2010.00819.x
SP  - 1
EP  - 106
PY  - 2010
ER  - 

AU  - Boyd, Jonathan W.
AU  - Prince, Nicole
AU  - Birringer, Marc
C7  - pp. 267-289
TI  - Future Research in Signaling
SN  - 9781119060260
UR  - https://doi.org/10.1002/9781119060208.ch9
DO  - doi:10.1002/9781119060208.ch9
SP  - 267-289
KW  - cellular signal transduction
KW  - crosstalk
KW  - nutrition research
KW  - pharmacology
KW  - posttranslational modifications
KW  - toxicology
PY  - 2010
AB  - Summary For cellular signal transduction research to reach its potential in toxicology and pharmacology, it is necessary to bridge the gap between early responses and end disease states. From the lessons learned in the drug development, it appears that there is much more research to be done before one can fully capitalize on cellular signal transduction research and translate it into clinical practice. Future research endeavors should seek to understand the spatial and temporal dependence of second messengers, as examples demonstrate the power that real-time, visual insights can provide to the field. Crosstalk is a form of signal integration, where seemingly independent signaling cascades are able to alter each other in response to stimulus. In order to improve the understanding of crosstalk, one must identify potential targets, including all of the potential sites that are available for posttranslational modifications. In the last few decades, nutrition research has undergone a dramatic transformation.
ER  - 

TY  - JOUR
AU  - Bangash, Mansoor N
AU  - Kong, Ming-Li
AU  - Pearse, Rupert M
TI  - Use of inotropes and vasopressor agents in critically ill patients
JO  - British Journal of Pharmacology
VL  - 165
IS  - 7
SN  - 9781119060260
UR  - https://doi.org/10.1111/j.1476-5381.2011.01588.x
DO  - doi:10.1111/j.1476-5381.2011.01588.x
SP  - 2015
EP  - 2033
KW  - inotrope
KW  - vasopressor
KW  - critical illness
KW  - haemodynamic shock
PY  - 2012
AB  - Inotropes and vasopressors are biologically and clinically important compounds that originate from different pharmacological groups and act at some of the most fundamental receptor and signal transduction systems in the body. More than 20 such agents are in common clinical use, yet few reviews of their pharmacology exist outside of physiology and pharmacology textbooks. Despite widespread use in critically ill patients, understanding of the clinical effects of these drugs in pathological states is poor. The purpose of this article is to describe the pharmacology and clinical applications of inotropic and vasopressor agents in critically ill patients. LINKED ARTICLES This article is commented on by Bracht et?al., pp. 2009?2011 and De Backer and Scolletta, pp. 2012?2014 of this issue. To view Bracht et?al. visit http://dx.doi.org/10.1111/j.1476-5381.2011.01776.x and to view De Backer and Scolletta visit http://dx.doi.org/10.1111/j.1476-5381.2011.01746.x
ER  - 

TY  - JOUR
TI  - Plenary Sessions
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - Basic Clin Pharmacol Toxicol
VL  - 125
IS  - S4
SN  - 9781119060260
UR  - https://doi.org/10.1111/bcpt.13301
DO  - doi:10.1111/bcpt.13301
SP  - 4
EP  - 55
PY  - 2019
ER  - 

TY  - JOUR
AU  - Prodinger, Christine
AU  - Reichelt, Julia
AU  - Bauer, Johann W.
AU  - Laimer, Martin
TI  - Epidermolysis bullosa: Advances in research and treatment
JO  - Experimental Dermatology
JA  - Exp Dermatol
VL  - 28
IS  - 10
SN  - 9781119060260
UR  - https://doi.org/10.1111/exd.13979
DO  - doi:10.1111/exd.13979
SP  - 1176
EP  - 1189
KW  - calcipotriol
KW  - diacerein
KW  - gene therapy
KW  - genodermatoses
KW  - squamous cell carcinoma
PY  - 2019
AB  - Abstract Epidermolysis bullosa (EB) is the umbrella term for a group of rare inherited skin fragility disorders caused by mutations in at least 20 different genes. There is no cure for any of the subtypes of EB resulting from different mutations, and current therapy only focuses on the management of wounds and pain. Novel effective therapeutic approaches are therefore urgently required. Strategies include gene-, protein- and cell-based therapies. This review discusses molecular procedures currently under investigation at the EB House Austria, a designated Centre of Expertise implemented in the European Reference Network for Rare and Undiagnosed Skin Diseases. Current clinical research activities at the EB House Austria include newly developed candidate substances that have emerged out of our translational research initiatives as well as already commercially available medications that are applied in off-licensed indications. Squamous cell carcinoma is the major cause of death in severe forms of EB. We are evaluating immunotherapy using an anti-PD1 monoclonal antibody as a palliative treatment option for locally advanced or metastatic squamous cell carcinoma of the skin unresponsive to previous systemic therapy. In addition, we are evaluating topical calcipotriol and topical diacerein as potential agents to improve the healing of skin wounds in EBS patients. Finally, the review will highlight the recent advancements of gene therapy development for EB.
ER  - 

TY  - JOUR
TI  - Synopses of papers presented at the 159th meeting of the Pathological Society of Great Britain and Ireland
JO  - The Journal of Pathology
JA  - J. Pathol.
VL  - 158
IS  - 4
SN  - 9781119060260
UR  - https://doi.org/10.1002/path.1711580412
DO  - doi:10.1002/path.1711580412
SP  - A335
EP  - A358
PY  - 1989
ER  - 

TY  - JOUR
TI  - 30th Annual Meeting of the Wound Healing Society SAWC-Spring/WHS Joint Meeting: Charlotte Convention Center, Charlotte, North Carolina, USA April 25–29, 2018
JO  - Wound Repair and Regeneration
JA  - Wound Rep Reg
VL  - 26
IS  - 1
SN  - 9781119060260
UR  - https://doi.org/10.1111/wrr.12622
DO  - doi:10.1111/wrr.12622
SP  - A1
EP  - A42
PY  - 2018
ER  - 

TY  - JOUR
C7  - e13383
TI  - Oral Sessions
JO  - Acta Physiologica
JA  - Acta Physiol
VL  - 227
IS  - S719
SN  - 9781119060260
UR  - https://doi.org/10.1111/apha.13383
DO  - doi:10.1111/apha.13383
SP  - e13383
PY  - 2019
ER  - 

TY  - JOUR
TI  - Monday Oral Session
JO  - Journal of Neurochemistry
VL  - 110
IS  - s2
SN  - 9781119060260
UR  - https://doi.org/10.1111/j.1471-4159.2009.06237.x
DO  - doi:10.1111/j.1471-4159.2009.06237.x
SP  - 1
EP  - 23
PY  - 2009
ER  - 

TY  - JOUR
TI  - Surgical research society abstracts
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 77
IS  - 6
SN  - 9781119060260
UR  - https://doi.org/10.1002/bjs.1800770635
DO  - doi:10.1002/bjs.1800770635
SP  - A691
EP  - A713
PY  - 1990
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - HPB
JA  - HPB
VL  - 17
IS  - S2
SN  - 9781119060260
UR  - https://doi.org/10.1111/hpb.12403
DO  - doi:10.1111/hpb.12403
SP  - 25
EP  - 266
PY  - 2015
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Tropical Medicine & International Health
JA  - Trop Med Int Health
VL  - 18
IS  - s1
SN  - 9781119060260
UR  - https://doi.org/10.1111/tmi.12163
DO  - doi:10.1111/tmi.12163
SP  - 108
EP  - 231
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Journal of Gastroenterology and Hepatology
VL  - 26
IS  - s5
SN  - 9781119060260
UR  - https://doi.org/10.1111/j.1440-1746.2011.06898.x
DO  - doi:10.1111/j.1440-1746.2011.06898.x
SP  - 16
EP  - 288
PY  - 2011
ER  - 
